AI

MP Group: Outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022′

We are glad to present our outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022’. The attached presentation outlines how AI can better elucidate disease biology and assist with building a robust hypothesis for target and biomarker identification. Most clinical trials fail because of poor safety and efficacy resultant from a lack of holistic disease understanding. The traditional approaches are usually unidimensional and fail to account for the complex nature of biology. While we are observing an explosion of healthcare data,…

Continue Reading

Outlook on AI and medical writing

We are glad to present our outlook on ‘AI and medical writing’ that gives an overall perspective on the technological advancements in the medical writing industry. Medical writing is expected to be a $5B+ market with a ~10% CAGR in the next 5 years. However, the industry faces the challenge of high attrition rates and lack of resources. Inefficiencies are further fueled by limited use of automation to reuse content between different regulatory documents and publications as well as limited…

Continue Reading

Biopharma Trend Article: Tech Providers or Biotechs: The Quest to Find an Optimal Business Model Continues for AI Drug Discovery Companies…

The AI drug discovery industry has already gathered momentum with AI start-ups having signed more than 200 deals with 50+ pharma companies over the last few years, and these are just the disclosed deals. Few top companies like InSilico Medicine and Cyclica claim to have over 100 collaborations each with Academia and Industries. With billions of dollars pouring-in, it is likely to gain further impetus with the industry approaching maturity in the next few years from its formative stage. A conundrum that…

Continue Reading

5 pitfalls AI healthcare start-ups need to avoid

Artificial intelligence (AI) has now moved beyond its initial hype towards becoming a key part of the pharma industry – with many companies looking to partner with AI drug discovery start-ups. Pharma and healthcare are data-rich industries and AI helps by turning data into actionable insights, allowing us to solve complex, intricate problems. Using machine learning, AI algorithms can generate patterns that will enable us to predict toxicity, find potential combination treatments, identify and predict new drugs and expand usage…

Continue Reading
Close Menu